Login to Your Account

FDA Panels Provide Late-Year Cheer With FluMist, Bexxar Nods

By Randall Osborne

Monday, December 23, 2002
Talk about a shot in the arm (or a squirt up the nose): The ailing biotechnology sector got a boost last week when FDA advisory panels gave their blessings to a pair of potentially important but historically beleaguered drugs - Corixa Corp.'s Bexxar for non-Hodgkin's lymphoma and MedImmune Inc.'s FluMist, a nasal influenza vaccine. (BioWorld Financial Watch)

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription